Sanquin Blood Supply Foundation
2
25M
1
0.50
- Areas of investment
Summary
The important activity for fund was in 2012. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 1 - 5 millions dollars are the general things for fund.
Among the most successful fund investment fields, there are Biotechnology, Therapeutics. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Xenikos
The usual cause for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are OostNL, Innovation & Investment Fund Gelderland. In the next rounds fund is usually obtained by RA Capital Management, Medicxi Ventures, Agentschap NL.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Follow on index
- 0.50
- Investments by industry
- Therapeutics (2)
- Life Science (2)
- Biotechnology (2)
- Investments by region
-
- Netherlands (2)
- Peak activity year
- 2012
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Xenikos | 19 Jun 2012 | Biotechnology, Life Science, Therapeutics | Early Stage Venture | 4M | Nijmegen, Gelderland, Netherlands |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.